GHB addiction: why stopping alone is dangerous

GHB addiction stands apart from almost every other substance because of its speed. The first withdrawal symptoms can begin 1 to 6 hours after the last dose, and stopping without medical supervision can be life-threatening (PMID 34073640).

There is a bitter logic to it. The same property that clears GHB from your body so fast is what makes the withdrawal so severe.

And that is exactly the problem we see at Zuivertest. Of all the substances we test, GHB is the one where a clean result says least about how you are actually doing.

What makes GHB so addictive?

The short duration of action. GHB is broken down quickly, so the effect falls away within hours and the need returns. With regular use this creates a pattern where people continue around the clock, including at night. That clock is the core of the dependence.

The body adapts to it fast. Where tolerance to alcohol builds over months to years, physical dependence on GHB can develop within weeks.

That explains why people are often caught off guard. They do not recognise themselves in the picture of an addict, and have meanwhile ended up in a schedule where they set an alarm.

What GHB does in your body during use is covered in our piece on GHB and its narrow margin.

What happens when you stop taking GHB?

The first symptoms usually begin within 1 to 6 hours: agitation, anxiety, sweating, tremor, palpitations and insomnia. The picture peaks in the first 24 to 48 hours and can then continue for 5 to 15 days. In some people, confusion or delirium develops (PMID 34073640).

Researchers mapped this pattern in patients in treatment. Anxiety, insomnia and tremor were the most common features, and the picture often escalated more steeply than with alcohol.

In a Dutch observational study of patients undergoing GHB detoxification, complications occurred despite medical supervision, including delirium and severe agitation (PMID 37864267).

That is with supervision. Without it, there is nobody watching it come.

Why is stopping GHB alone dangerous?

Because GHB suppresses the nervous system, and that system can swing hard when it is suddenly removed. Confusion, hallucinations, a sharply raised heart rate and seizures have all been described. The picture resembles severe alcohol withdrawal, but starts earlier and moves faster (PMID 34073640, PMID 28004314).

In the Netherlands and Belgium, detoxification is therefore usually done clinically, with tapering using pharmaceutical GHB or benzodiazepines compared and applied under supervision (PMID 32319006). That is work for a clinician.

We deliberately give no tapering schedule and no doses here. Not out of caution, but because that schedule differs per person and requires supervision.

If you notice confusion, hallucinations, heavy tremor or a seizure in yourself or someone else, seek medical help immediately. Call your GP, the out-of-hours service outside working hours, and 112 for a seizure.

How long is GHB detectable in a test?

Briefly. GHB is often detectable in urine for less than 12 hours, and in blood for even less. That is the shortest window of any substance Zuivertest tests. It creates the most misleading situation in this whole subject: your test is clean while your withdrawal has not yet begun.

Put the two clocks side by side and the picture speaks for itself.

The right-hand column is empty after two days, while the middle column is only then at its worst. Picture someone who stops on Monday evening and hands in urine for a screening 36 hours later. That result comes back negative.

At that moment they are in the middle of the peak.

That is not a fault in the lab. It is exactly what the test is meant to do: measure exposure, not withdrawal. How long GHB stays visible and what that depends on is set out in how long GHB stays detectable.

What can you have tested yourself?

You can have a certified laboratory establish per substance what is in your sample, with a quantified value instead of a line on a strip. For people who used other substances alongside GHB, a broader panel gives a fuller picture than a single test.

The extended 10-panel covers the substances that most often occur together in practice. If you would rather choose the substances yourself, you can build your own panel.

Be honest about what such a result gives you. It shows which substances were in your sample at that moment. It says nothing about dependence, nothing about how much you used, and nothing about how severe your withdrawal will be.

What it does do is fix a date. Testing at set intervals during a recovery period builds a series of dated results, and that is something different from one isolated snapshot.

RIVM publishes monitoring and risk assessments of substances circulating in the Netherlands, and Thuisarts.nl describes when to see a GP about problematic use.

If you take one thing from this: with GHB, the test is the least informative part of the story. I would honestly reverse the order here, make the appointment first and think about testing afterwards. Discuss stopping with a doctor before you stop, not afterwards.

How this pattern compares with other substances is covered in our overview of withdrawal symptoms by substance. For the mirror image with a stimulant, see cocaine addiction, and for the other dangerous withdrawal see alcohol withdrawal.

Every blood test result at Zuivertest includes a professional assessment by a BIG-registered doctor. Discuss your results with your GP before making treatment decisions.

Sources

• Kamal RM, Dijkstra BAG, van Noorden MS et al., "Characterization of the GHB Withdrawal Syndrome", Journal of Clinical Medicine, 2021 (PMID 34073640)
• Dijkstra BAG, Beurmanjer H, Goudriaan AE et al., "GHB: a life-threatening drug, complications and outcome of GHB detoxification treatment, an observational clinical study", Addiction Science and Clinical Practice, 2023 (PMID 37864267)
• Beurmanjer H, Kamal RM, de Jong CAJ et al., "Tapering with Pharmaceutical GHB or Benzodiazepines for Detoxification in GHB-Dependent Patients: A Matched-Subject Observational Study of Treatment-as-Usual in Belgium and The Netherlands", CNS Drugs, 2020 (PMID 32319006)
• Kamal RM, van Noorden MS, Wannet W et al., "Pharmacological Treatment in gamma-Hydroxybutyrate (GHB) and gamma-Butyrolactone (GBL) Dependence: Detoxification and Relapse Prevention", CNS Drugs, 2017 (PMID 28004314)
• RIVM, drug monitoring and risk assessment of psychoactive substances (rivm.nl)
• Thuisarts.nl, information on problematic substance use (thuisarts.nl)